Bone Marrow Transplant (BMT)
Show Only Open Trials
1.
Lenalidomide, Bortezomib and Dexamethasone vs High-Dose Treatment with Peripheral Stem Cell Transplant in Myeloma Patients Up to Age 65
- Study Status: Open to Enrollment
- Sponsor: Dana Farber Cancer Institute
- Disease Status and/or Stage: Untreated Multiple Myeloma
2.
CALGB 100801: Phase II Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older patients With AML
- Study Status: Closed to Enrollment
- Sponsor: CALGB
- Disease Status and/or Stage: Acute Myeloid Leukemia and Myelodysplasia
- Protocol ID: CALGB 100801
3.
Tocilizumab (an anti-human IL-6 receptor monoclonal antibody) as a first line therapy for patients with glucocorticoid-refractory acute graft vs. host disease (aGVHD) after allogeneic hematopoietic stem cell transplant (HSCT), a Phase II study
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Steroid-Refractory Acute Graft-versus-Host Disease (GVHD)
4.
A Randomized Controlled Study of Extracorporeal Photopheresis (ECP) Therapy with UVADEX™ for the Treatment of Patients with Moderate to Severe Chronic Graft versus Host Disease (cGVHD)
- Study Status: Open to Enrollment
- Sponsor: Therakos
- Disease Status and/or Stage: Moderate to Severe Graft-versus-Host Disease (GVHD)
5.
RDCRN 6503: Targeted Therapy of Bronchiolitis Obliterans Syndrome
- Study Status: Open to Enrollment
- Sponsor: NIH, GVHD Consortium
- Disease Status and/or Stage: Bronchiolitis Obliterans Syndrome (BOS) after Hematopoietic Cell Transplant (HCT)
6.
RDCRN 6502: A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis after Allogeneic Hematopoietic Cell Transplantation
- Study Status: Open to Enrollment
- Sponsor: NIH, GVHD Consortium
- Disease Status and/or Stage: Cutaneous Sclerosis after Hematopoietic Cell Transplant (HCT); blood disorders; rituximab; imatinib; Sebastian Mayer MD; Weill Cornell Bone Marrow Transplant; stem cell transplant; New York Presbyterian Hospital
- Protocol ID: RDCRN 6502
7.
Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)
- Study Status: Open to Enrollment
- Sponsor: Fresenius Biotech GmbH
- Disease Status and/or Stage: Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- Protocol ID: IV-ATG-SCT-01
8.
RDCRN 6501: Longitudinal study of Immune Mediated Disorders after Allogeneic Hematopoietic Cell Transplantation
- Study Status: Open to Enrollment
- Sponsor: NIH, GVHD Consortium
- Disease Status and/or Stage: Planned or Completed First Allogeneic Stem Cell Transplant
9.
A multicenter safety study of unlicensed, investigational cryopreserved cord blood units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for unrelated hematopoietic stem cell transplantation of pediatric and adult patients
- Study Status: Open to Enrollment
- Sponsor: National Cord Blood Program
- Disease Status and/or Stage: Hematologic Malignancies and Other Indications Receiving Allogeneic Hematopoieic Stem Cell Transplant
10.
Lenalidomide plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Relapsed/Refractory Multiple Myeloma
11.
A Randomized study of Combined Haplo-identical Umbilical Cord Transplantation vs. Double Umbilical Cord Transplantation in Patients with Hematologic Malignancies
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Hematologic Malignancies in Need of Donor Stem Cell Transplant
12.
A Prospective Study of Optimally Matched-IPA Targeted Haplo-cord Transplantation
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Hematologic Malignancies in Need of Donor Stem Cell Transplant
13.
BMT CTN 0903 - Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals
- Study Status: Open to Enrollment
- Sponsor: BMT-CTN
- Disease Status and/or Stage: Hematologic Cancers and Myelosysplastic Syndromes in HIV-Positive People
- Protocol ID: BMT CTN 0903
14.
CPX-351 as Salvage Chemotherapy Followed by a Reduced Intensity Conditioning (RIC) Stem Cell Transplantation Utilizing Double Umbilical Cord Blood (dUCB) Grafts for Patients with Relapsed or Refractory Leukemia
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Relapsed/Refractory Leukemia
